

What is claimed is:

1. A method for *in situ* detection of a nucleic acid analyte within a sample of biological
5 material based on bDNA hybridization comprising the steps of:

(a) preparing the sample of biological material by:

(i) immobilizing the biological material on a substrate;

(ii) permeabilizing the substrate-bound biological material by contacting the
10 substrate-bound biological material to a solution containing Proteinase K at a
concentration of about 0.5 µg/ml to about 50 µg/ml; and

(iii) optionally heating the permeabilized biological material to a temperature and
for a time period effective to denature any double-stranded DNA;

(b) contacting the biological material with a target oligonucleotide probe under
hybridizing conditions, wherein at least a portion of the target probe is complementary to
15 at least a portion of the nucleic acid analyte, so that an analyte-target probe complex is
formed when the nucleic acid analyte is present in the sample;

(c) washing the biological material with a washing fluid comprising a detergent, at a
temperature in the range of approximately 21 to 60 °C; and

(d) detecting any analyte-target probe complex on the substrate.

2. The method of claim 1, wherein step (d) comprises:

(d)(i) contacting the washed substrate and analyte-target probe complex with a
preamplifier oligonucleotide probe under hybridizing conditions, wherein a first portion
of the preamplifier probe is complementary to a portion of the target probe other than the
25 portion of the target probe that is complementary to the nucleic acid analyte, thereby
forming an analyte-target probe-preamplifier probe complex when the nucleic acid
analyte is present in the sample;

(d)(ii) contacting the product of step (d)(i) with an amplifier oligonucleotide probe under
hybridizing conditions, wherein a first portion of the amplifier probe is complementary
30 to a second portion of the preamplifier probe, thereby forming an analyte-target
probe-preamplifier probe-amplifier probe complex when the nucleic acid analyte is

present in the sample;

(d)(iii) contacting the product of step (d)(ii) with a label oligonucleotide probe under hybridizing conditions, wherein a portion of the label probe binds to a second portion of the amplifier probe, thereby forming an analyte-target probe-preamplifier

probe-amplifier probe-label probe complex when the nucleic acid analyte is present in the sample;

(d)(iv) labeling the analyte-target probe-preamplifier probe-amplifier probe-label probe complex with a detectable label; and

(d)(v) detecting the presence of the label on the substrate.

3. The method of claim 1, wherein the nucleic acid analyte is selected from the group consisting of HIV RNA, HIV DNA, HCV RNA, CMV RNA, CMV DNA, HPV RNA, HPV DNA, LAP, IL-2, endogenous genes and segments thereof.

4. The method of claim 1, wherein the substrate comprises glass or a resilient plastic.

5. The method of claim 1, wherein the concentration of Proteinase K is from about 5 $\mu\text{g/ml}$ to about 20 $\mu\text{g/ml}$.

6. The method of claim 1, wherein approximately 0.1 pmoles to 10 pmoles of the target probe is used.

7. The method of claim 1, wherein the detergent in the washing fluid is a hydrophilic surfactant.

8. The method of claim 7, wherein the hydrophilic surfactant is non-ionic.

9. The method of claim 1, wherein the washing fluid is a buffer solution.

10. The method of claim 10, wherein the buffer solution comprises the salts of alkali metals.

11. The method of claim 1, wherein step (c) is repeated at least once.

12. The method of claim 11, wherein step (c) is repeated at least twice.

13. The method of claim 1, wherein step (c) is carried out at from about 21 °C to about 60 °C.

14. The method of claim 2, wherein approximately 1 fmole to about 10 pmoles of the preamplifier oligonucleotide probe is used.

15. The method of claim 2, wherein approximately 1 fmole to about 10 pmoles of the amplifier oligonucleotide probe is used.

16. The method of claim 2, wherein the label oligonucleotide probe comprises alkaline phosphatase.

17. The method of claim 16, wherein an alkaline phosphatase substrate is added to detect the presence of the label.

18. The method of claim 1, having a sensitivity sufficient to detect from 1 to about 10 copies of the nucleic acid analyte.

19. The method of claim 18, having a sensitivity sufficient to detect from 1 to about 2 copies of the nucleic acid analyte.

20. The method of claim 1, wherein the biological sample comprises a cell.

21. The method of claim 20, wherein the cell is isolated from the group consisting of plasma, serum, spinal fluid, semen, lymph fluid, the external sections of the skin, secretions of the respiratory tract, secretions of the intestinal tract, secretions of the genitourinary tract, tears, saliva, milk, blood cells, tumors, organs and in vitro cell culture constituents.

22. The method of claim 20, wherein the cell is selected from the group consisting of adrenal, bladder, bone marrow, brain, breast, cardiac, colon, esophageal, intestinal, kidney, liver, pulmonary, lymph node, nerve, ovarian, pancreatic, prostatic, skeletal muscle, smooth muscle, spleen, stomach, testicular, tonsil, tracheal and uterine cells.

23. The method of claim 20, wherein step (a)(i) is carried out using a centrifuge.

24. The method of claim 1, wherein the biological sample comprises a tissue.

25. The method of claim 24, wherein the tissue is selected from the group consisting of adrenal, bladder, bone marrow, brain, breast, cardiac, colon, esophageal, intestinal, kidney, liver, pulmonary, lymph node, nerve, ovarian, pancreatic, prostatic, skeletal muscle, smooth muscle, spleen, stomach, testicular, tonsil, tracheal and uterine tissues.

26. The method of claim 24, wherein step (a)(i) is carried out using sections of the tissue.

27. A method for identifying the position of a nucleic acid analyte within a sample of biological material based on bDNA hybridization comprising the steps of:

(a) preparing the sample of biological material by:

(i) immobilizing the biological material on a substrate;

(ii) permeabilizing the substrate-bound biological material by contacting the substrate-bound biological material to a solution containing Proteinase K at a concentration of about 0.5 µg/ml to about 50 µg/ml; and

(iii) optionally heating the permeabilized biological material to a temperature and

- for a time period effective to denature any double-stranded DNA;
- (b) contacting the biological material with a target oligonucleotide probe under hybridizing conditions, wherein at least a portion of the target probe is complementary to at least a portion of the nucleic acid analyte, so that an analyte-target probe complex is formed when the nucleic acid analyte is present in the sample;
- (c) washing the biological material with a washing fluid comprising a detergent, at a temperature in the range of approximately 21 to 60 °C;
- (d) detecting any analyte-target probe complex on the substrate; and
- (e) identifying the position of the analyte-target probe complex within a cell of the biological sample as indicative of the position of the nucleic acid analyte in the cell.

28. A method for detecting a nucleic acid analyte within a sample of biological material comprising performing bDNA hybridization to detect the nucleic acid analyte *in situ*, wherein the method has a sensitivity sufficient to detect from about 1 to about 10 copies of the nucleic acid analyte in the biological material.

29. The method of claim 28, wherein the nucleic acid analyte is selected from the group consisting of HIV RNA, HIV DNA, HCV RNA, CMV RNA, CMV DNA, HPV RNA, HPV DNA, LAP, IL-2, endogenous genes and segments thereof.

30. The method of claim 28, wherein the sensitivity is sufficient to detect from 1 to about 2 copies of the nucleic acid analyte.

31. The method of claim 28, wherein the biological material comprises a cell.

32. The method of claim 31, wherein the cell is isolated from the group consisting of plasma, serum, spinal fluid, semen, lymph fluid, the external sections of the skin, secretions of the respiratory tract, secretions of the intestinal tract, secretions of the genitourinary tract, tears, saliva, milk, blood cells, tumors, organs and in vitro cell culture constituents.

33. The method of claim 31, wherein the cell is selected from the group consisting of adrenal, bladder, bone marrow, brain, breast, cardiac, colon, esophageal, intestinal, kidney, liver, pulmonary, lymph node, nerve, ovarian, pancreatic, prostatic, skeletal muscle, smooth muscle, spleen, stomach, testicular, tonsil, tracheal and uterine cells.

5

34. The method of claim 28, wherein the biological sample comprises a tissue.

35. The method of claim 34, wherein the tissue is selected from the group consisting of adrenal, bladder, bone marrow, brain, breast, cardiac, colon, esophageal, intestinal, kidney, liver, pulmonary, lymph node, nerve, ovarian, pancreatic, prostatic, skeletal muscle, smooth muscle, spleen, stomach, testicular, tonsil, tracheal and uterine tissues.

10

15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500